Table 3 Results from cost–utility analysis of the changes in patient management and reproductive planning
Parameter | Changes in management (patient only) | Changes in management, cascade testing, and reproductive outcomes (patient and first-degree relatives) |
|---|---|---|
QALYs gained | A$1.25 | A$9.99 |
Total cost of treatments and surveillance started due to WES result | A$14,233.65 | A$14,708.65 |
Total savings from treatments and surveillance ceased due to WES result | A$16,206.00 | A$16,206.00 |
Cost of cascade testing | NA | A$28,000.00 |
Total cost of reproductive service use (diagnosed and undiagnosed groups) | NA | A$56,904.14 |
ICER | –A$1577.88 | A$8118.70 |
95% CI | –A$205,449.67 to A$19,780.25 | A$1961.84 to A$38,943.90 |
